Departments & Services
Clinical Trials
Intro Copy
The Penn State Hershey Cancer Institute at Mount Nittany Medical Center continues to participate in clinical research in the areas of prevention and treatment of cancer, and has experienced tremendous growth since its establishment.
Details
For more information, call 814.231.7813.
Clinical trials offer cancer patients new treatments that have been developed after long and painstaking research processes. Still, there can be no certainties with any new approach, thus the need to continue to study the new therapies. Cancer patients treated on well-organized clinical trials, in general, do as well or better than patients receiving “standard” treatments, particularly in difficult cancers where traditional treatments have not had a high success rate.
Breast
Adjuvant
| ECOG/S0221 | A Phase III Trial continuous schedule AC + G vs. q2 wk schedule AC, followed by Paclitaxel given earlier every 2 wks or weekly for 12 wks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer. ECOG/S0221 Clinical Abstract (PDF) |
| ECOG/S0230 | Phase III Trial of LHRH Analog Admin. During Chemo to Reduce Ovarian Failure Following Chemo in Early Stage, Hormone-Receptor Negative Breast Cancer. ECOG/S0230 Clinical Abstract (PDF) |
| PACCT-1 (TAILORx) | Program for the Assessment of Clinical Trial Tests (PACCT-1): Trial Assigning Individualized Option for Treatment The TAILORx Trial. PACCT-1 (TAILORx) Clinical Abstract (PDF) |
| RTOG 0413/B-39 | Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer. RTOG 0413/B-39 Clinical Abstract (PDF) |
| BETH | A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy plus Trastuzumab plus Bevacizumab. BETH Clinical Abstract (PDF) |
| E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. E5103 Clinical Abstract (PDF) |
| NSABP-B43 | A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. NSABP-B43 Clinical Abstract (PDF) |
Metastatic
| NO733 | Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane. NO733 Clinical Abstract (PDF) |
GI
Adjuvant
| E5202 | A Randomized Phase III Study Comparing 5-FU, Leucovorin & Oxaliplatin vs. 5-FU Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer. E5202 Clinical Abstract (PDF) |
Metastatic
| CALGB/SWOG 80405 | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplation/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. CALGB/SWOG 80405 Clinical Abstract (PDF) |
Melanoma
Adjuvant
| E1697 | A Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T3-T4 or N1 (microscopic) Melanoma. (Huntingdon) E1697 Clinical Abstract (PDF) |
Thoracic
Adjuvant
| E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non Small Cell Lung Cancer (NSCLC) E1505 Clinical Abstract (PDF) |
| S0819 | A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carbolpatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). S0819 Clinical Abstract (PDF) |
| PSHCI 08-009 | A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC). PSHCI 08-009 Clinical Abstract (PDF) |
Leukemia
| E2903 | Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia. E2903 Clinical Abstract (PDF) |
| E3903 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders. E3903 Clinical Abstract (PDF) |
| C10404 | A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia. C10404 Clinical Abstract (PDF) |
| E1905 | A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia. E1905 Clinical Abstract (PDF) |
Lymphoma
| C50303 | Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas. C50303 Clinical Abstract (PDF) |
Bone
| RTOG 0517 | A Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zolendronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast and Prostate Cancer. RTOG 0517 Clinical Abstract (PDF) |
Head and Neck
| E1305 | A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer. E1305 Clinical Abstract (PDF) |
Multiple Myeloma
| E1A06 | An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not candidates for High-Dose Therapy. E1A06 Clinical Abstract (PDF) |
GU
| NCIC PR.11 | A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START). NCIC PR.11 Clinical Abstract (PDF) |
Please direct any questions to a Penn State Hershey Cancer Institute Trials Office staff member:
Barbara Gutch, RN, OCNClinical Research Coordinator Phone: 814.231.7843 | Cheryl DePaolis, RNClinical Research Coordinator - Phone: 814.359.8696 |
Amy Long, BS, CCRPData Manager Phone: 814.231.7810 | Samantha Moyer, RN, BSNClinical Research Coordinator Phone: 814.231.7813 |
© 2010 Mount Nittany Medical Center : 1800 East Park Avenue, State College, PA 16803-6797 : ph. (814) 231-7000